Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06502392

Correlation Between Creatine Phosphokinase and Pelvic Floor Muscle Strength in Postnatal Women

The purpose of this study is to determine the correlation between creatine phosphokinase and pelvic floor muscle strength in post-partum women.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pelvic Floor; Rupture, Old (Postpartum) Rupture Wounds and Injuries

Age range

25 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

Hadeer Mostafa

Giza, Egypt

Location status: Recruiting

Location contact

Manal El-Shafei, PhD

CONTACT

About this study

Pelvic floor disorders (PFDs) are complex conditions affecting women's quality of life, including issues like pelvic organ prolapse, urinary incontinence, and pelvic pain. These disorders are prevalent, with 2.6-28.7% of women experiencing urinary incontinence and 20-50% suffering from pelvic organ prolapse. Accurate diagnosis requires a comprehensive understanding of pelvic musculoskeletal components and the interaction of multiple body systems.

Creatine phosphokinase (CPK) activity can be elevated in various conditions, including muscle diseases, burns, and after strenuous exercise. During childbirth, increased serum CPK levels have been observed, attributed to enzyme release from the uterus and placenta. CPK levels typically return to normal within six weeks postpartum.

To date, no study has explored the correlation between CPK levels and pelvic floor muscle strength in postnatal women. This research aims to fill this knowledge gap, potentially benefiting medical services and expanding understanding in women's health physical therapy.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post-partum women who delivered vaginally.
  • Their ages will range from 25 to 35 years old.
  • Their body mass index (BMI) will be <30 Kg/m2.
  • CPK will be measured within the first six weeks (2nd-5th weeks) after delivery for all women.

Exclusion criteria

  • Any dysfunction or associated injury or any pathological conditions which may affect the result of the study as cardiac abnormalities, thyroid dysfunction recurrent urinary tract infections, uncontrolled hypertension or diabetes mellitus.
  • History of pelvic inflammatory disease, myoma and tumors, pelvic infection, ovarian cyst, any gynecological disease, any hormonal abnormality and any psychological problem.
  • Pelvic floor dysfunction: genital prolapse, incontinence.
  • Previous surgical operations as hysterectomy.
  • Inability to understand the written and verbal instructions.

Treatment and study plan

Assessment of creatine phosphokinase

Other

Assessment will be done through collecting a blood sample.

Assessment of pelvic floor muscle strength

Other

Assessment will be done by a biofeedback.

Primary outcomes

  1. Assessment of creatine phosphokinase

    Time frame: It will be measured within the first six weeks after delivery (2nd-5th weeks).

    It will be assessed through collecting a blood sample. The collected blood will be transferred into a sterile vacutainer tubes (9 mL) with anticoagulant and will be placed symmetrically into the centrifuge device. The serum will be separated from blood and will be put in epindoorf tubes and send immediately for analysis. Serum CPK will be quantitatively measured in units/liter (u/l) on a Vitros 950 automated analyzer shortly after the receipt of the specimen.

  2. Assessment of pelvic floor muscle strength

    Time frame: It will be measured within the first six weeks after delivery (2nd-5th weeks).

    It will be assessed by a biofeedback. Women will be positioned comfortably for pelvic floor muscle (PFM) strength assessment using a TG Myo feedback 420v vaginal electrode. The electrode, properly prepared and inserted, will measure vaginal closure pressure and deep PFM strength. The therapist will explain the display and will establish a one-minute baseline, noting any inconsistencies. Women will perform three 10-second maximum contractions, with the mean of these readings to be recorded. Muscle strength will be measured by peak maximum pressure and ability to sustain contraction.

  3. Assessment of pelvic floor muscle endurance

    Time frame: It will be measured within the first six weeks after delivery (2nd-5th weeks).

    It will be assessed by a biofeedback. Women will be positioned comfortably for pelvic floor muscle endurance assessment using a TG Myo feedback 420v vaginal electrode. The electrode will be properly prepared and inserted. The therapist will explain the display and will establish a one-minute baseline, noting any inconsistencies. Women will perform three 10-second maximum contractions. Muscle endurance will be measured as the time a sub-maximum contraction can be maintained before significant power reduction occurs.

Study contacts

Contact information is provided by the study sponsor or research team.

Hadeer Mostafa, B.Sc

CONTACT

[email protected]

01140561470

Manal El-Shafei, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jul 16, 2024
Registry last updated
Aug 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.